Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in sprague dawley rats

Journal of Pharmaceutical Sciences

Volumn 96, Issue 9, 2007, Pages 2494-2506

  Hassan, Hazem E ^a   Myers, Alan L ^a   Lee, Insong J ^a   Coop, Andrew ^a   Eddington, Natalie D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Blood brain barrier (BBB); Caco 2 cells; Distribution; Drug transport; P glycoprotein

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CARBON 14; GLYCOPROTEIN P; OXYCODONE; PACLITAXEL; VERAPAMIL;

AFFINITY LABELING; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; BRAIN LEVEL; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DISTRIBUTION; ENZYME ASSAY; HUMAN; HUMAN CELL; KIDNEY; LIQUID SCINTILLATION COUNTING; LIVER LEVEL; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; STIMULATION; TISSUE DISTRIBUTION; WESTERN BLOTTING;

EID: 34748829961     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20893     Document Type: Article

References (45)

1. Smith H. 2003. Drugs for Pain. 1st edition. Philadelphia: Hanely and Belfus. pp 83-155.
2. Stimmel B. 1997. Pain and Its Relief Without Addiction. 2 edition. New York: The Haworth Medical Press. pp 123-172.
3. Ronold M, Patrick W. 2003. Hand Book of Pain Managment. 1st edition. New York: Churchill Livingstone. pp 377-396.
4. Dagenais C, Graff CL, Pollack GM. 2004. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67:269-276.
5. Callaghan R, Riordan JR. 1993. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem 268:16059-16064.
6. Zong J, Pollack GM. 2000. Morphine antinociception is enhanced in mdr1a gene-deficient mice. Pharm Res 17:749-753.
7. Gottesman MM, Pastan I. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
8. Pastan I, Gottesman MM. 1991. Multidrug resistance. Annu Rev Med 42:277-286.
9. Borst P, Evers R, Kool M, Wijnholds J. 2000. A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295-1302.
10. Zaman GJ, Flens MJ, van Leusden MR, de Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, Borst P. 1994. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A 91: 8822-8826.
11. Kharasch ED, Hoffer C, Whittington D, Sheffels P. 2003. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 74:543-554.
12. Letrent SP, Polli JW, Humphreys JE, Pollack GM, Brouwer KR, Brouwer KL. 1999. P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. Biochem Pharmacol 58:951-957.
13. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL. 1999. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 27:827-834.
14. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL. 1998. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and phar-macodynamics in the rat. Pharm Res 15:599-605.
15. Dagenais C, Zong J, Ducharme J, Pollack GM. 2001. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharm Res 18: 957-963.
16. Aquilante CL, Letrent SP, Pollack GM, Brouwer KL. 2000. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci 66:PL47-PL51.
17. Joranson DE, Ryan KM, Gilson AM, Dahl JL. 2000. Trends in medical use and abuse of opioid analgesics. Jama 283:1710-1714.
18. Jette L, Beaulieu E, Leclerc JM, Beliveau R. 1996. Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 270:F756-F765.
19. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G. 2002. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110:1309-1318.
20. Glantz MJ, Choy H, Kearns CM, Mills PC, Wahlberg LU, Zuhowski EG, Calabresi P, Egorin MJ. 1995. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 87:1077-1081.
21. Heimans JJ, Vermorken JB, Wolbers JG, Eeltink CM, Meijer OW, Taphoorn MJ, Beijnen JH. 1994. Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol 5:951-953.
22. Loscher W, Potschka H. 2005. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22-76.
23. Bostrom E, Simonsson US, Hammarlund-Udenaes M. 2005. Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor P SC833. J Pharm Sci 94: 1060-1066.
24. Ross FB, Wallis SC, Smith MT. 2000. Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Pain 84:421-428.
25. Nielsen CK, Ross FB, Smith MT. 2000. Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the Dark Agouti rat. J Pharmacol Exp Ther 295:91-99.
26. Woofle G, Macdonald A. 1944. The evaluation of the analgesic action of pethidine hydrochloride (demerol). J Pharmcol Exp Ther 80:300-307.
27. Gallo JM, Li S, Guo P, Reed K, Ma J. 2003. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 63: 5114-5117.
28. Kemper EM, Cleypool C, Boogerd W, Beijnen JH, van Tellingen O. 2004. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 53:173-178.
29. Dawson M, Fryirs B, Kelly T, Keegan J, Mather LE. 2002. A rapid and sensitive high-performance liquid chromatography-electrospray ionization-triple quadrupole mass spectrometry method for the quantitation of oxycodone in human plasma. J Chromatogr Sci 40:40-44.
30. Polli JE, Rekhi GS, Augsburger LL, Shah VP. 1997. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J Pharm Sci 86:690-700.
31. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
32. Matsunaga T, Kose E, Yasuda S, Ise H, Ikeda U, Ohmori S. 2006. Determination of p-glycoprotein ATPase activity using luciferase. Biol Pharm Bull 29:560-564.
33. Litman T, Zeuthen T, Skovsgaard T, Stein WD. 1997. Structure-activity relationships of P-glycoprotein interacting drugs: Kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta 1361:159-168.
34. Crowe A. 2002. The influence of P-glycoprotein on morphine transport in Caco-2 cells. Comparison with paclitaxel. Eur J Pharmacol 440:7-16.
35. Crowe A, Lemaire M. 1998. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin. Pharm Res 15:1666-1672.
36. Wandel C, Kim R, Wood M, Wood A. 2002. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96:913-920.
37. Thompson SJ, Koszdin K, Bernards CM. 2000. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 92:1392-1399.
38. Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC. 1999. The role of P-glycoprotein in blood-brain barrier transport of morphine: Transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Pharmacol 128:563-568.
39. Bell MD. 2006. Response to paclitaxel, gemcitabine, and cisplatin in renal medullary carcinoma. Pediatr Blood Cancer 47:228.
40. Tono T, Iwazawa T, Matsui S, Yano H, Kimura Y, Kanoh T, Ohnishi T, Nakano Y, Okamura J, Monden T. 2004. Hepatic arterial infusion of paclitaxel for liver metastasis from gastric cancer. Cancer Invest 22:550-554.
41. Dagenais C, Ducharme J, Pollack GM. 2001. Uptake and efflux of the peptidic delta-opioid receptor agonist. Neurosci Lett 301:155-158.
42. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. 2000. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 294:73-79.
43. King M, Su W, Chang A, Zuckerman A, Pasternak GW. 2001. Transport of opioids from the brain to the periphery by P-glycoprotein: Peripheral actions of central drugs. Nat Neurosci 4:268-274.
44. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW. 2002. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303: 1029-1037.
45. Raje S, Cao J, Newman AH, Gao H, Eddington ND. 2003. Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. J Pharmacol Exp Ther 307:801-808.